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Abstract
Introduction
Radiation therapy has been limited in the treatment of locally advanced pancreatic cancer. This is
due to the dose tolerance to nearby organs at risk and breathing motion. Advancements in radiation
treatment technology have now allowed pancreatic patients to be treated to higher doses in fewer
fractions using stereotactic body radiotherapy treatment. With the use of MRI-guided treatments,
using the ViewRay MRIdian linac, doses can be escalated using online adaptive treatment planning
and real time tracking. However, there has yet to be an optimal breathhold technique investigated
that can aid in this process.
Methods
Five patients that had been previously treated on the institutions ViewRay MRIdian linac to the
pancreas were evaluated. A deep inspiration and end exhale plan were created for each patient
using the ViewRay TPS. The treatment goals followed the SMART trial protocol guidelines. The
prescription was 50 Gy treated in 5 f(x)s at least every other day. CTV goal coverage was 100%
of the volume to 95% of the prescription dose and luminal OARs (stomach, duodenum, small
intestine, and large intestine) to not exceed 33 Gy to 0.5 cc. A step and shoot intensity modulated
radiation therapy technique was used.
Results
A nonparametric sign test was performed, and there was no statistically significant difference in
the coverage of the CTV by the 95% isodose line. There was also no significant data found in the
volume of the duodenum or stomach that received 33 Gy to 0.5 cc or the volume of the two organs
within the zPTV_PRV30 planning ring.
Conclusion
An optimal gating technique was not discovered. A larger study group and further research is
necessary to produce significant data.
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Introduction
Pancreatic cancer is slowly becoming a common cause of cancer mortality, it is projected
that it will become the second leading cause of cancer death in the United States.1 The only chance
for cure of this disease is surgical resection. However, 80-85% of patients that present with
pancreatic cancer often present with advanced disease and are not surgical candidates, leading to
a 5-year survival rate of ~10%. Even with surgical resection the prognosis is dim with
approximately 20% surviving at 5-years.1
Most pancreatic cancers are adenocarcinomas and are located in the pancreatic head. Due
to this location one common symptom is jaundice due to the blockage of the nearby biliary duct.1
Other symptoms may include abdominal pain, nausea or vomiting, indigestion, back pain, changes
in stool consistency and/or weight loss. These vague symptoms can lead to a delay in diagnosis
adding to the reason of why these patients are often diagnosed at a later stage of disease, some
patients have no symptoms at all. The first stage of diagnosis is with a diagnostic computed
tomography (CT) scan. The scan can delineate between the hypodense cancer tissue and the
pancreas.1 A CT alone may tell whether or not a tumor is resectable by showing local tumor
extension.2 A magnetic resonance image (MRI) may also be used to help visualize possible liver
metastases, and an endoscopic ultrasound which can be used to identify lymph nodes and nearby
vascular structures.1 When the dismal prognosis is given patients are then placed into different
categories for staging; resectable, borderline resectable, locally advanced, and metastatic.1
Unfortunately, treatment options for pancreatic cancer are limited and even though surgery
is the only cure there is still a high rate of recurrence post surgery.2 When adding chemotherapy
and radiation (CRT) post surgery the survival rates almost double from 10.9 months to 21 months.2
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Preoperative CRT has yet to be established as a treatment standard but is being used more and
more for resectable and borderline resectable disease.1,2 Studies are currently being completed
comparing these two treatment techniques.1 For unresectable disease, patients can receive CRT or
more commonly chemotherapy alone.2 Chemotherapy alone is often the treatment modality used
for widely metastatic disease, however, radiation can also be used to palliate symptomatic
disease.1,2
For neoadjuvant and adjuvant radiation therapy the simulation technique for treating
pancreatic cancer is the same. Patients are simulated in the supine position with the standard being
arms supported up over the head. This allows the arm to be outside of the treatment field.2 If
patients cannot maintain the arms up position and their arms are down by their side they will have
to be avoided while planning so that the arms are not in the treatment fields. Contrast can be used
both orally and intravenously to delineate the duodenum and vascular landmarks.2 Because the
pancreas lies just below the diaphragm motion can affect the imaging and treatment process. To
account for this a 4D computed tomography scan can be used for simulation. A 4DCT scan
acquires images at different breathing phases and will show the movement of the pancreas and aid
in treatment planning.2 Another option to limit motion is through the use of respiratory gating by
either having a patient hold their breath at the top, inspiration breath hold, or the bottom, exhalation
breath hold.
Breathing motion is one of the greatest downfalls in treating upper abdominal cancers with
radiation therapy. Continual motion from breathing is not the only limiting factor but also normal
involuntary motion, such as peristalsis and motion of gas,3 can all affect the location of targets and
organs at risk (OARs). Farrugla et al. reported that there was considerable difficulty controlling
tumor position in voluntary breath holds by 12.5% of patients.3 Most patients spend their time in
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the end exhale (EE) position and often conventional free-breathing treatments are planned in this
phase,4 and it is well known that it is a more reproducible technique for the treatment of upper
abdominal cancers.3 However, this technique has been found to be more challenging, and in need
of more breaths when treating, than compared with end inhale, which is a more sustainable gating
technique for patients.5
Stability and reproducibility of breath holds are paramount in treating pancreatic
adenocarcinomas to obtain optimal target coverage while limiting dose to critical structures. The
conventional treatment of pancreatic adenocarcinoma has many limitations due to the surrounding
organs at risk and motion, with the biggest limiting factor being the duodenum. It has been
previously reported by Taniguchi et al. that using the end expiration phase can result in a decrease
in dose to the duodenum. This is because respiration causes the relationship to change between the
duodenum and the pancreatic tumor. “The V20 to the duodenum averaged 5.9 cc when planned on
end expiration and 7.2 cc when planned on end inspiration.”4 Little is known about how much
other organs at risk are displaced or how much their volume has changed between these two
techniques in the treatment of pancreatic cancer. It is standard to control breathing motion in the
treatment of abdominal cancers using gating techniques with inspiration breath hold being the most
common.
The traditional treatment regimen for treating pancreatic cancer is 45-50.4 Gray (Gy) in
25 to 30 fractions6 using 3D-conventional or more commonly, intensity modulated radiation
therapy (IMRT). IMRT has proven to be superior with the allowance of dose escalation through
simultaneous integrated boosts. Dose escalation, along with chemotherapy has improved overall
survival and locoregional control 3-fold.6 Advancements in radiation treatment technology have
now allowed pancreatic patients to be treated to higher doses in fewer fractions using stereotactic
5

body radiotherapy treatment (SBRT) technique7. A common dose fractionation schedule is 50 Gy
in 5 fractions. Treating to these higher doses emphasizes the significance of protecting critical
structures while still delivering accurate doses to the target, again stressing the importance of
internal motion.8
One important limitation to using conventional linear accelerators is imaging. Even with
advancements in technology, such as the use of cone beam computed tomography (CBCT),
visualization of soft tissue is still difficult. This is due to increased noise level and poor soft-tissue
contrast when compared to a diagnostic CT scan.9 Fiducials in and/or around the target can help
with visualization, as they can monitored with the use of image guided radiotherapy (IGRT)2, but
that leads to more imaging and increases dose to the patient. Tracking fiducials may aid in
visualization of the location of the target but does not show other internal organ movement. MRI
is the standard imaging modality for soft tissue imaging. Now through the use of MRI guided
radiation therapy we can image while treating, without giving extra dose to the patient.9
Stereotactic MRI guided radiation therapy (SMART) is a relatively new treatment modality
that can be used in the treatment of pancreatic adenocarcinoma.10 It allows real time visualization
of internal organ movement while treating simultaneously. The superior image quality allows for
the use of online adaptive planning which aiding in the potential to dose escalate while still
protecting normal tissue.11 Adaptive therapy is not a new technique, it is often used when
replanning for patient changes whether it is weight loss, set-up inaccuracies or target changes.12
However, this process is usually done offline and does not take into account normal internal organ
motion that occurs during that days treatment.12 A entirely new plan is generated with offline
adaptive planning and patients frequently have to go through the entire simulation process again,
possibly delaying the patient’s treatment.
6

To overcome these potential delays and internal daily changes, MRI-guided online
adaptive radiotherapy allows the treatment plan to be adjusted while the patient is on the table.
Studies have shown that day to day changes can vary as much as 2cm13, this could be virtually
unknown using CBCT only due to poor soft tissue visualization. Online adaptive planning uses
the original treatment plan and the image taken from that day’s treatment, generates a new plan
that considers the intrafractional changes. Adaptive planning can often be lengthy so to help cut
down on treatment planning time deformable registrations of contours in the ViewRay system are
utilized. Also, the plans are reoptimized with the same parameters from the original plan.13 The
method allows for recontouring and generating new plans to give more accurate doses to targets
and OARs. Adaptive replanning has shown to improve tumor coverage while decreasing dose to
the duodenum.14 Another advantage to online adaptive treatment is that air in the gastrointestinal
can be accounted for and is beneficial as air in the stomach greatly affects dose to the PTV and
surrounding organs.14,15 Both the ViewRay MRIdian and the Elekta MRI-linac are able to employ
online adaptive planning with real-time tracking and gating functionality.13
Even with these advancements it is still unknown what occurs to target, OAR volumes and
doses between end inhale vs end exhale treatments. The goal of this study is to determine one
technique is more optimal than the other, DI or EE, in the treatment of locally advanced pancreatic
adenocarcinoma using the ViewRay MRIdian treatment planning system. The null hypothesis is
that they are the same with the alternative hypothesis being that they are not the same. If they are
not the same it will lead to more investigation.

Methods
Patient Selection
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This retrospective dosimetric analysis included five patients with locally advanced
pancreatic cancer that had previously been treated with MRI guided SBRT. The subjects were
anonymized and therefore no identifiable background information is known. The inclusion criteria
were patients that had previously been treated using a deep inspiration breathhold (DIBH) gating
technique and treated on the ViewRay MRIdian LinacTM (ViewRay, Inc., Oakwood Village, Ohio,
USA).
Simulation
Each patient was simulated using a GE lightspeed 16RT computed tomography (CT)
scanner. Prior to their appointment they were instructed to not have anything to eat or drink four
hours prior to their procedure (NPO). They were in the supine position with arms by their side,
centered on the simulation table with MRI coils underneath and above them. A 3D simulation was
obtained while the patient was instructed to hold their normal inhale breath. Patients were coached
to not hold their deepest breath to enhance reproducibility. The CT simulation scans were not used
for planning purposes. They were used to confirm isocenter placement and to obtain the correct
Hounsfield units for dosimetric purposes. Once the CT was obtained the patients were marked at
the isocenter that the MD selected. They were then given 8 ounces of water to drink, to aid in
visualization of the duodenum on the MRI, and transferred over to the MRI linac for the next
portion of the simulation.
During the MRI simulation the patients were set-up in the same position as on the CT table.
Two MRIs to be used for treatment planning were obtained. One with the same inspiration breath
as was instructed during the CT (MRD) and one while the patient was holding the exhale portion
of their breathing cycle (MREE). The patients were treated using the inspiration technique due to

8

physician choice. After the simulation scans were complete patients were given tattoos for aid in
reproducing the setup when treated.
IRB
A Data Review Protocol was submitted to Dartmouth Health and found to be exempt. The
protocol outlined the background, endpoints and methods for the study. Also, any potential risks
and how they were mitigated relating to the privacy and protection of patient’s and patient
information. The patients in this study were anonymized by the primary invistigator and all
identifying information was restricted on a password protected internal system. There were no
medical risks for the participation subjects and there was a minimal risk of loss of confidentiality
should access be gained to the password protected data linking the anonymized identification to
patient medical record numbers. The study was also submitted the Grand Valley State University
(GVSU) Institutional Review Board (IRB) and approved under the exempt review category.
Planning
For this retrospective analysis the original planning computed tomography (CT) and
ViewRay MRI, DI and EE, scans were anonymized, registered, and imported into the ViewRay
treatment planning system (VR-TPS), for a total of ten treatment plans. The planning and
contouring parameters that were followed were from ViewRays SMART trial protocol for the
treatment of LAPC (VR C2T2 – SMART- LAPC/BRPC 1).
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The same physician and resident

contoured the targets and relevant organs at risk (OARs) on the MRI images. The gross tumor
volume (GTV) was contoured and then expanded to include the superior mesenteric vessel and
celiac axis nodes (CTV). Then a planning target volume (PTV) was created to encompass the CTV
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with a 3mm expansion. The OARs included the small bowel, large bowel, duodenum and stomach.
They were contoured on all slices 3cm superior and inferior to the PTV.
The plans were completed by the same two dosimetrists to ensure the same process was
used for all patients. The dosimetrists reviewed the given contours and created the necessary
planning structures. Rules were created and used in the treatment planning system to create the
following optimization structures and were exactly the same for all patients. The first structure was
a PTV optimization structure (PTV_OPT) which is done by subtracting the PTV from any
overlying OARs. Next a ring was created around the PTV by expanding the PTV volume 3cm in
the sagittal and coronal direction and 1.5 cm in the axial (zPTV_PRV30). Then the OARs within
this volume were booleaned together (zOARs_3). An optimization structure was created to give
0.3cm of fall off between the PTV and zOARs_3 (zOptPTV High) as the OARs were the limiting
dose factor. Then dose rings were created, an inner ring (zInner) by expanding the PTV by 3mm
and subtracting it from the zPTV_PRV30 and a mid ring (zMid), a 3cm expansion on
zPTV_PRV30 and then subtract zPTV_PRV30. If the zMid expands outside the body it was
cropped to be within the skin structure. See figure 1 in the appendix.
Once all planning structures were created the next step of the process was to confirm the
fusion from the imported CT scan and confirm the correct isocenter. Then in the beams section of
the TPS beams were placed. The goal was to use as many beams as possible without any directly
opposing one another. A range from 19-21 beams was used. Beams that traveled through the
patient’s arms or the beveled edge of the treatment table were removed. The prescription dose was
confirmed as well as the default electron density table: 22.5 mm. The table factor was selected as
the DHMC Scanner. Sequencing was set to 40 segments and Bixels set to an IMRT efficiency of
8. In the dose tab the magnetic field was set to yes and geometry to 0.2cm.
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Next, objectives and constraints were created. A max constraint of 32 Gy was added to the
zOARs_3, 1 Gy under the prescription max of 33 Gy. A max dose constraint of 65 Gy was also
added to the PTV, this is 130% of the PTV. In the SMART trial protocol, which was used as a
guideline when treating pancreas patients, the max dose to the PTV is 140%. These two constraints
were activated and then the objectives are created. The goal was to maximize dose to the PTV
without going over the dose limits to the OARs and to limit 50% of the dose outside of the
zPTV_PRV30. The zOptPTV_High, zInner, zMid and skin were used as starting objectives with
specific priorities and thresholds, these had the ability be adjusted after the initial optimization.
See figure 2 in the appendix. The plan was then optimized and coverage was assessed. If the nearest
limiting OAR was not meeting the constraint of 0.5cc to 33Gy, each plan was dose escalated by
normalizing the plan lower to meet the limit of the OAR. To maximize coverage to the target,
without going over OAR constraints, the thresholds and powers of the objectives were also
adjusted in the optimization process. This ensures the patient is receiving the highest dose to the
tumor.

Results
The goal of this study was to determine if there was an optimal gating technique between
deep inspiration breath hold and end expiration breath hold for online adaptive treatment planning
for locally advanced pancreatic cancer. The CTV, stomach and duodenum were evaluated for dose
coverage and volume changes for five previously treated patients. The duodenum and the stomach
were especially important organs at risk as they were the most common dose limiting structures.
CTV
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According to the SMART Trial protocol, the target dose to the CTV is 100% of the volume
to receive 95% of the prescription dose, or 47.5Gy.16 This coverage was assessed for both the DI
and EE plans. A nonparametric sign test was performed, and there was no statistically significant
difference in the coverage of the CTV by the 95% isodose line in the DI CTV volume (M=95.396,
SD = 3.59) and EE CTV volume (M = 91.698, SD = 6.896) p = 0.125. See figure 3 and table 3 in
the appendix. Only two patients were able to achieve the CTV coverage objective for both the
deep inspiration and end exhale scans, patients two and three. Due to the limited number of patients
and the possibility of one number skewing the data, each patient was evaluated individually.
Greater than 90% of the CTV volume was covered by the 95% isodose line in patients one, two
and three for the DI and EE plans. For the DI plans, the CTV volume covered by the 95% isodose
line was 94.69%, 100% and 97.88% and 92.29%, 100%, and 96.55% respectively. Patients four
and five had the worst coverage on both plans, 90.91% and 93.5% for DI and 86.04% and 83.61%
for EE. See table 1 in the appendix. The SMART Trial protocol allows for the CTV dose to fall
within the range of 60-90% of the volume receiving 95% of the prescription dose. The minimum
volume coverage of the CTV at 95% of the prescription dose was acceptable at 90.91% for the DI
and 83.61% for EE plans, see Table 2 descriptive statistics in the appendix.
Duodenum
According to the SMART trial protocol, the dose to the OARs are not to exceed 33 Gy to
0.5 cc of the organ.16 Due to the nature of planning on the ViewRay, the entire organs at risk were
not contoured beyond five centimeters from the PTV. The treatment planning goal was to keep the
33 Gy isodose line within a three-centimeter ring around the PTV (zPTV_PRV_30), therefore only
the volume of the duodenum that lies within the 3 cm ring was evaluated in all the plans. The
amount of duodenum within the zPTV_PRV_30 was not found to be a statistically significant
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difference for the DI plan (M=53.492, SD = 28.494) or the EE plan (M=58.752, SD = 30.859) p =
.375. See figure 4 and tables 2 and 3 in the appendix. Again, due to the sample size the patients
were evaluated individually. Only one patient, patient one, had a decrease in volume of the
duodenum from the DI to the EE plan, in which the volume of the duodenum decreased from
74.2cc to 67.51cc. In patients two through five, the volume of the duodenum increased from the
DI to the EE plans, 18.45cc to 20.67cc, 36.41cc to 38.51cc, 48.94cc to 65.59cc and 88.94cc to
101.48cc respectively. See table 1 in the appendix.
In five out of the ten total plans it was the duodenum that determined the normalization of
the plans. Patient’s one, four, and the EE of patient five were normalized down so that the
duodenum met the maximum dose constraint, 33 Gy to 0.5cc. For patient two the duodenum in the
DI plan received 33 Gy to 0.26cc and 0.18cc on the EE plan. With patient three the duodenum
received 0.39 cc to 33 Gy on the DI plan and 0.43 cc on the EE. Oddly, the DI plan on patient five
was normalized to the small bowel and the volume of the duodenum the received 33 Gy was
0.47cc. See table 1 in the appendix. The volume of small bowel that received 33 Gy on the exhale
scan was 0.06cc. There was no significant data between the DI (M=.424, SD=.102) and EE plans
(M = .422, SD = .139) p = 1.000 for the volume receiving 33 Gy. See figure 5 and tables 2 and 3
in the appendix.
Stomach
There was no statistical significance in the change of volume of the stomach between the
DI (M = 53.094, SD =23.502) to the EE (M = 46.556, SD = 19.2698) p = 0.375. See figure 6 and
tables 2 and 3 in the appendix. The volume of the stomach within the zPTV_PRV30 decreased
from the DI to the EE plans in four out of five patients. Patient five had the biggest difference in
volume from the DI 77.79cc to 56.63cc in the EE plan. Patients one, two and three decreased from
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65.5cc, 63.8cc, 19.49cc for the DI plans to 60.91cc, 60.0cc and 15.79cc for the EE plans. Patient
four had a slight increase from DI 38.89cc to EE 39.45cc. See table 1 in the appendix.
There was also no significance found between the DI (M = .306, SD = .185) and EE (M =
.232, SD = .250) plans for the volume that received 33 Gy, p = .250. See figure 7 and tables 2 and
3 in the appendix. Four out of the ten plans were normalized to the stomach with the same absolute
volume-based constraint of 33 Gy to 0.5cc. This occurred in patients two and three. The volume
receiving 33 Gy in patients one, four and five was 0.2cc, 0.24cc and 0.09cc for the DI plans and
0.14cc, 0.02cc and 0cc for the EE plans. See table 1 in the appendix.

Discussion
The purpose of this study was to determine if there was a more optimal gating technique,
deep inspiration versus end exhale, in the treatment of locally advanced pancreatic
adenocarcinoma, regarding target coverage and the sparing of organs at risk using the ViewRay
MRIdian Linac. The challenge in treating this area with radiation is due to target and OAR motion
from breathing, peristalsis, and the movement of bowel gasses.3 Previous literature has shown that
patients spend more time in the end exhale phase of breathing and conventional free breathing
treatments are planned in this phase.4 For patients that are treated using a gating technique, deep
inspiration breath hold is the most common due to it being more sustainable for patients.5 With the
advancement of technology and employment of the ViewRay MRIdian, online adaptive planning
with real time imaging and tracking can be used in the treatment of LAPC.10 This treatment
technique has shown to improve target coverage while decreasing dose to the OARs.14 An optimal
gating technique has yet to be discovered.
CTV
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Though there was no significant data supporting a gating technique, there were some trends
that were observed. CTV coverage was worse in four out the five exhale plans compared to the
deep inspiration plans at the prescription target coverage of 95% of the dose to 100% of the target
volume. Only two patients were able to meet the objective. However, the SMART trial protocol
that was used for treating these plans states that because the OARs are the limiting dose factor the
volume of the CTV that receives 95% of the prescription dose often falls between 60-90%. If this
was taken into consideration then all ten plans were acceptable in the protocol standards.16 All five
inhale plans also showed over 90% coverage. Patient’s four and five showed the largest difference
in coverage from the inhale to the exhale plans. The limiting factor for coverage of the target
greatly depended on the normalization of the OAR structures. For this group of patients, the most
common was the duodenum and the stomach.
Duodenum
The sample size being small aided in the lack of statistical significance and increased the
importance of finding trends between the individual patients became valuable. The duodenum is
the closest OAR to the pancreatic head and was found to be the dose limiting structure in five out
of the ten treatment plans. Patient’s one, four and five were all normalized to the duodenum limit
of 0.5 cc to 33 Gy in three exhale and two inhale plans. The volume of the duodenum that fell
within the zPTV_PRV30 in all the plans was the largest in all three of these patients. Possibly
leading to why it was the most common dose limiting structure, location and size. The only
difference was the inhale plan on patient five was normalized to the small bowel. However, the
duodenum was almost at its constraint with 0.47 cc receiving 33 Gy. Patient five also had the
greatest difference in the volume of the duodenum, 88.94 cc in the DI plan and 101.48 cc in the
exhale plan. With the patient being NPO for four hours prior to their simulation it can possibly be
15

assumed that the difference in the size of the duodenum was due to the different breathholds and
not because of other factors, such as peristalsis. However, the 8 ounces of water introduces some
bias. The slight trend that the duodenum was the dose limiting structure in three of the exhale
plans did not follow previous literature.
It had been previously reported that the dose to the duodenum was higher in patients that
used a deep inspiration breath hold technique.4 The hypothesis our study group had was the
potential for the compression of the organs in the DI breath hold would lead to more of the OARs
being exposed to higher doses. The volume of the duodenum that received 33 Gy from the exhale
to the inhale plans showed a decrease in four out of five patients, which does not support the
previous theory. Three of the five patients were normalized to the duodenum in the EE plans
compared to only two for the inhale plans. The patients that were normalized to the stomach had
the smallest duodenal volume in all the plans.
Stomach
The stomach was the other most common limiting OAR structure. It was normalized in
both the DI and EE plans for patients two and three. Aside from patients two and three, the volume
of the stomach that received 33 Gy was marginally larger in all three remaining patients for the DI
plans. The volume of the stomach within the zPTV_PRV30 was larger in four out five patients,
possibly aiding to why a larger volume received 33 Gy. However, patient four had a marginal
decrease in volume within the zPTV_PRV30 from the EE to DI of 0.56cc. This did not aid in any
statistical significance.
Limitations and Future Research
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The major limitation in this study was the sample size. Only five patients were assessed
and without any major deviations there was no statistically significant data. There was also no way
to gauge how a patient was holding their breath. Breath holds are rarely consistent,3 and it is
unclear what the instructions were for breath holding, whether or not to use a belly or a chest
breath. There were also a lot of variables that could have been used for evaluation with such a
small sample size finding the correct ones were extremely difficult. Other variables that could have
influenced the target coverage were also not evaluated, such as air near the target or if the 8 ounces
of water was affecting volume due to peristalsis. With further research and a larger sample size it
may be possible that an optimal gating technique could be found.
One possible further addition to this study would be to do a prospective study on an endexhale plan and a free breathing treatment. Studies have shown that most patients spend their time
in an exhale phase in a normal breathing pattern and that it is more reproducible than DI. With real
time tracking the technique could possibly be used in the advancement of treating locally advanced
pancreatic cancer. This could lead to shorter treatment times and be more comfortable for the
patient. Another aid to shorter treatment times and patients hitting their breathing targets is the use
of visual gating aids where patients are able to see their breathing target and adjust their breath to
reach that target, making them more in control of their treatment.

Conclusion
Locally advanced pancreatic cancer is an aggressive cancer with a dismal outlook. The
only chance for a cure is surgical resection.1 Due to the limited amount of patients that are
candidates for surgical resection, radiation is often used as a common treatment modality.2
Radiation is still limited because of high gastrointestinal (GI) toxicity because of the adjacent
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organs at risk that are so near to the pancreas.8 Another challenge for radiation treatment is the
motion from breathing and other involuntary motions such as peristalsis and the motion of gas
through the GI system.3 To overcome some of these limitations institutions often use a gating
technique during radiation treatment.
There was no statistically significant data for this study regarding CTV coverage and the
sparing of OARs between the DI and EE plans. Coverage was acceptable in all the plans according
to the SMART trial protocol. The stomach and the duodenum were the most common limiting
structures. Further evaluation is needed to determine if there is an optimal gating technique.
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Appendix
Table 1.

Table 2.
Descriptive Statistics
Percentiles
N

Mean

Std. Deviation

Minimum

Maximum

25th

50th (Median)

75th

Inhale_CTV

5

95.3960

3.59112

90.91

100.00

92.2050

94.6900

98.9400

Inhale_DuodenumV33

5

.4240

.10213

.26

.50

.3250

.4700

.5000

Inhale_StomachV33

5

.3060

.18542

.09

.50

.1450

.2400

.5000

Inhale_DudenumV3

5

53.4920

28.49406

18.45

88.94

27.4300

48.9400

81.8300

Inhale_StomachV3

5

53.0940

23.50214

19.49

77.79

29.1900

63.8000

71.6450

Exhale_CTV

5

91.6980

6.89645

83.61

100.00

84.8250

92.2900

98.2750

Exhale_DuodenumV33

5

.4220

.13864

.18

.50

.3050

.5000

.5000

Exhale_StomachV33

5

.2320

.25044

.00

.50

.0100

.1400

.5000

Exhale_DuodenumV3

5

58.7520

30.85903

20.67

101.48

29.5900

65.5900

84.4950

Exhale_StomachV3

5

46.5560

19.26983

15.79

60.91

27.6200

56.6300

60.4550

Table 3.
Test Statisticsa

Exhale_CTV Inhale_CTV
Exact Sig. (2-tailed)

.125b

Exhale_Duoden

Exhale_Stomac

Exhale_Duoden

Exhale_Stomac

umV33 -

hV33 -

umV3 -

hV3 -

Inhale_Dudenu

Inhale_Stomach

mV3

V3

Inhale_Duodenu Inhale_Stomach
mV33

V33

1.000b

a. Sign Test
b. Binomial distribution used.
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.250b

.375b

.375b

Figure 1. Ring creation

Figure 2. Objectives starting point
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Figure 3. Mean CTV coverage of the 95% isodose line

Figure 4. Mean duodenal volume within zPTV_PRV_30
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Figure 5. Mean duodenal volume receiving 33 Gy within zPTV_PRV_30

Figure 6. Mean stomach volume within zPTV_PRV_30
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Figure 7. Mean stomach volume receiving 33 Gy within zPTV_PRV_30
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